IQVIA's $34 billion backlog, and what it means for the people who work it

IQVIA is the largest CRO on earth, and in Q1 2026 it reported the kind of numbers that go with the title: $4.15 billion in quarterly revenue and an R&D Solutions backlog of $34.2 billion, up from $32.9 billion. For the roughly 93,000 people who work there, backlog is not an abstraction. It is the pile of contracted work their jobs exist to deliver. Here is how to read it.

Steady, not spectacular

IQVIA's R&D book-to-bill was 1.04 for the quarter and 1.11 on a trailing twelve-month basis. That is above the 1.0 line, so the backlog is still growing, but it is short of the roughly 1.2 that analysts consider robust. The company noted the 1.04 was held down by an unusually low mix of pass-through bookings, the reimbursed costs that flow through a CRO's books, so the underlying booking was a bit stronger than the headline. Net new bookings rose to $2.5 billion from $2.2 billion a year earlier.

The read for workers is stability rather than surge. A $34.2 billion backlog, with about $8.9 billion of it set to convert to revenue in the next twelve months, is an enormous cushion of contracted work. That cushion is why IQVIA's staffing is less volatile than a smaller CRO's: it has years of booked work to deliver regardless of any single soft quarter. Scale buys stability.

The scale caveat

That same scale means IQVIA's headline numbers hide a lot. IQVIA is not only a CRO; it is also a health-data and technology company, and more than 31,000 of its 93,000 employees are in technology roles. So its overall figures blend clinical research with data and analytics businesses that behave differently. When you read "IQVIA is hiring" or "IQVIA is cutting," the question is always which IQVIA, because the clinical research organization and the technology arm are different labor markets under one name.

The demand signal

IQVIA also gave the clearest read on the upstream recovery. It flagged emerging biopharma funding near $25 billion in the quarter, roughly double a year earlier, with a reopening IPO window and rising proposal flow. That money is where future trials come from, and its return is the real reason to expect the backlog to keep growing. It is an uneven, fits-and-starts recovery, in management's own framing, not a clean V, but the direction is up.

What the filing cannot tell you

A $34 billion backlog tells you IQVIA has years of work booked. It does not tell you what a CRA or biostatistician there actually clears, how the company handles the difference between its clinical and technology workforces, or whether a given team is growing or being squeezed to protect margin. Those are the questions that decide whether IQVIA is a good place to work right now, and no filing answers them. The people inside do. If you work at IQVIA, add your datapoint, and put a real number on the largest employer in the industry.